Last Updated:
Create account to add to watchlist!
Create account to add to watchlist!

Chavant Capital Acquisition Corp. - CLAY

  • Commons



    CLAY Vol: 1.9K

  • Warrants



    CLAYW Vol: 25.4K

  • Units



    CLAYU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 0.0
Average Volume: 0.0
52W Range: $0.00 - $0.00
Weekly %: +0.00%
Monthly %: +0.00%
Inst Owners: 43


Target: Searching
Days Since IPO: 388
Unit composition:
Each unit has an offering price of $10.00 and consists of one ordinary share and three-quarters of one redeemable warrant
Trust Size: 10000000.0M

🕵Stocktwit Mentions

CandyTurdMan posted at 2022-08-03T17:10:23Z

$CLAY starlink??

macroaxis posted at 2022-07-30T04:03:05Z

$CLAY - Chavant Capital exotic insider transaction… #insidertrading #stocks #fintechnews

Quantisnow posted at 2022-07-29T14:01:54Z

$CLAY 📜 SEC Form 3: New insider Polar Asset Management Partners Inc. claimed ownership of 320,000 units of Ordinary shares 45 seconds delayed.

Newsfilter posted at 2022-07-29T14:00:56Z

$CLAY Form 3 (initial statement of beneficial ownership of securities) filed with the SEC

WaterWings posted at 2022-07-27T01:04:53Z

$CLAY At the rate this is going, I could be one of the last guys watching this one before the end of the month

prka posted at 2022-07-21T12:06:25Z

$CLAY stupid question but I can’t find anywhere what does target company do?

bulbulu posted at 2022-07-21T10:27:19Z


jrittle posted at 2022-07-21T04:22:02Z

$CLAY zero borrow here and already at 25% fee. If this is under 11 tomorrow I'm gonna start biting. Good risk/reward

mtunik posted at 2022-07-20T19:14:54Z

$CLAY NAV protection? 3.8% downside risk

bulbulu posted at 2022-07-20T16:22:53Z

$PGY Check out $CLAY Similar theme.

supermark99 posted at 2022-07-20T16:00:14Z

$CLAY some dumb people on clay and mond. $MOND i like the story these pumpers try and tell you lmao. Comparing them to other charts but forgetting to show you all the failed spacs. Lmao

boyyyy posted at 2022-07-20T15:36:49Z

$CLAY omg the pumpers are back, didnt they learn first time

Bruceswingsteen posted at 2022-07-20T15:36:47Z

$CLAY it wasn’t pretty but just sold for a small gain that’s why I went small on this so I could hold through the volatility

boyyyy posted at 2022-07-19T23:01:12Z

$CLAY what a disaster of a pump this was

Bruceswingsteen posted at 2022-07-19T21:28:10Z

$CLAY added a couple more small on the dip I’ll swing nav protected low float

prka posted at 2022-07-19T21:03:17Z

$CLAY this fizzled quickly….we have 6 weeks

Bruceswingsteen posted at 2022-07-19T20:40:03Z

$CLAY added small for a big move

Alejos11 posted at 2022-07-19T20:35:31Z

$CLAY Looks good for the next six weeks 🐎

CrytiCaII posted at 2022-07-19T20:34:29Z

🎯 Momentum continuing in $CLAY and heading for 14. Made 8.7% already. 🔹 Price: 13.48 🚀 Float: 8.3M 🔥 Short Float: 0.0% 💰 Dollar Volume: 69.6K ℹ️ USA | Shell Companies ❗ 5 minutes delayed.

YonezuInvesting posted at 2022-07-19T20:29:48Z

$CLAY New lowest float NAV protected SPAC, just confirmed via SEC filing. 953k float 7.05m out of 8m redeemed (88% redemption) Previous lowest NAV protected SPAC was $DUNE at 1.18m shares

ZelFinance posted at 2022-07-19T20:29:32Z

$CLAY nice🔥

Last10K posted at 2022-07-19T20:28:49Z

$CLAY just filed with the SEC a New Agreement, a New Financial Obligation, a Bylaw Change, a Vote of Security Holders, a Regulated Disclosure and a Financial Exhibit

cctranscripts posted at 2022-07-19T20:23:33Z

Entry into a Material Definitive $CLAY

Quantisnow posted at 2022-07-19T20:19:58Z

$CLAY 📜 Chavant Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits 45 seconds delayed.

risenhoover posted at 2022-07-19T20:19:48Z

$CLAY / Chavant Capital Acquisition files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 14, 2022 CHAVANT CAPITAL ACQ

Newsfilter posted at 2022-07-19T20:19:26Z

$CLAY Form 8-K: Entry into a Material Definitive Agreement. On July 18, 2022, Chavant Capital Acquisition Corp. issued an unsecured convertible note in the aggregate principal amount of up to $490,000..

Last10K posted at 2022-06-30T21:17:07Z

$CLAY just filed with the SEC a Regulated Disclosure

Quantisnow posted at 2022-06-30T21:14:24Z

$CLAY 📜 SEC Form DEFA14A filed by Chavant Capital Acquisition Corp. 45 seconds delayed.

cctranscripts posted at 2022-06-30T20:52:10Z

Chavant Capital Acquisition: Soliciting Material Pursuant To §240.14A-12 Chavant Capital Acquis $CLAY

Newsfilter posted at 2022-06-30T20:51:36Z

$CLAY Form DEFA14A (additional definitive proxy soliciting materials and rule 14(a)(12) material) filed with the SEC


Our officers, directors and director nominees are as follows: Name Age Title Jiong Ma 57 Chief Executive Officer, President and Director André-Jacques Auberton-Hervé 59 Chairman of the Board of Directors Michael Lee 45 Chief Financial Officer Karen Kerr 52 Director nominee Bernhard Stapp 65 Director nominee Patrick J. Ennis 57 Director nominee Dr. Jiong Ma has been our Chief Executive Officer and President since March 2021. Since November 2020, Dr. Ma has been a Venture Partner at Braemar Energy Ventures (“Braemar”), an energy-focused venture capital firm. From 2008 to October 2020, Dr. Ma served as Senior Partner and a member of the investment committee at Braemar. While at Braemar, Dr. Ma has led investments in more than 15 companies involved in either resource efficiency, e-mobility, industrial digitalization, renewable energy, or deep tech, and has achieved multiple successful exits through M&A and IPO. During her career, she has served on the board of directors of more than 10 venture-backed companies, including Powervation (acquired by ROHM Semiconductor Ltd.), Convery Computer (acquired by Micron Technology, Inc.), mc10 (acquired by Medidata), and Carbonite Inc., which went public in 2011 and was subsequently acquired by OpenText (Nasdaq: OTEX) in 2019 for $1.45 billion. Dr. Ma currently serves on the board of Anavex Life Sciences Corp. (Nasdaq: AVXL) and as an advisory board member for each of Demeter Partners, a VC/PE fund dedicated to ecological and energy transformation in Europe, and National Renewable Energy Labs, a national laboratory of the U.S. Department of Energy which develops solutions to transform the generation, consumption, storage, and distribution of energy. From 2004 to 2008, Dr. Ma was an investment professional with the venture capital arm of 3i, a global private equity firm, where she led investments across multiple stages in technology and media, digital health, and cleantech. From 1997 to 2004, Dr. Ma held numerous senior positions at Lucent Technologies and Nortel Networks, where she was responsible for portfolio strategy, product development and research and development. In 2000, Dr. Ma co-founded Onetta Inc., an optical networking company, which was acquired by Bookham Technology in 2004. Dr. Ma holds a PhD in Electrical and Computer Engineering from the University of Colorado at Boulder, an MS in Electrical Engineering from Worchester Polytechnic Institute, and a BS in Physics and Electrical Engineering from Lanzhou University in China. Dr. Ma is also a Kauffman Fellow. Dr. Ma’s experiences in technology innovation, finance, and operations across multiple stages of business enable her to provide valuable leadership and expertise to our board of directors. Dr. André-Jacques Auberton-Hervé will serve as the Chairman of our board of directors following the completion of this offering. Dr. Auberton-Hervé serves as Chairman Emeritus of Soitec, a leader in Silicon-On-Insulator (SOI) technologies with a market capitalization of over $6 billion and a constituent company in the CAC Mid 60 Index, which he co-founded in 1992 out of a government laboratory and took public in Paris on the Euronext Stock Exchange in 1999. Serving for 23 years as Soitec’s President and Chief Executive Officer from July 1992 to January 2015, Dr. Auberton-Hervé was responsible for overseeing the company’s strategic, operational and financial activities that spanned across ten countries with five manufacturing facilities in Europe, Asia and the U.S. Dr. Auberton-Herve is the founder of 4A Consulting & Engineering, which provides strategic advice and consulting services with respect to renewable energy and digital innovation, and has served as its President and CEO since its founding in July 2015. In 2016, he became an operating partner of C4 Ventures, a leading European venture capital fund founded by Pascal Cagni (VP & GM EMEIA, Apple Inc., 2000-2012). In February 2018, he founded ATAJ, a company that he manages and that operates as advisor to Sofinnova Partners, a leading French venture capital fund, and its Sofinnova IT FPCI fund. Since January 2018, Dr. Auberton-Hervé has served as Chairman of the board of Bionik Laboratories Corp. In 2013, Dr. Auberton-Hervé was elected as Chairman of International Board of Directors of SEMI, the preeminent global industry association representing the electronics manufacturing industries. Dr. Auberton-Hervé is a recipient of numerous industry accolades, including the Audacity in Creativity Award from French President Jacques Chirac and the INSEAD Entrepreneurship Prize. Dr. Auberton-Hervé holds a doctorate degree with distinction in Physics from Ecole Centrale de Lyon. He is also a knight of the French Legion d’Honneur and the Ordre national du Mérite. 100 Dr. Auberton-Hervé’s entrepreneurial, technical and executive experience growing Soitec into a multibillion-dollar speciality electronic materials company, his stature as an international leader in advanced electronic materials, and his extensive experience and relationships make him highly qualified to serve on our board of directors to assist with our ultimate business combination transaction. Michael Lee has been our Chief Financial Officer since March 2021. Mr. Lee has over 22 years of experience in private equity and finance. He is currently the managing member of New Highland LLC, a finance consultancy for start-ups which he joined in 2013. Previously, from 2001 to 2013, Mr. Lee was a Director at Lincolnshire Management, a private equity firm, where he managed acquisitions and corporate divestitures and served in officer and board member roles of portfolio companies. Mr. Lee started his career at the merchant banking division of Wachovia Bank. He received a BA in Economics, magna cum laude, from Princeton University. Dr. Patrick Ennis will serve as a director following the completion of this offering. Dr. Patrick Ennis has over 30 years of experience as a scientist, engineer, businessman and venture capitalist. Since April 2019, Dr. Ennis has been a Venture Partner at Madrona Venture Group, a venture capital and private equity group focused on early-stage technology companies. Since April 2016, Dr. Ennis has served as a Director at Wipro Limited (NYSE: WIT), a global information technology, consulting and business process services company. From 2008 to March 2019, Dr. Ennis served as Global Head of Technology at Intellectual Ventures, a private equity firm specializing in invention, where he had responsibility for incubation, seed investments and technology commercialization, along with primary responsibility for investments in Asia. In January 2016, Dr. Ennis was the co-founding CTO of Xinova, a pioneer in global innovation market networks, and served as its CTO from inception to March 2019. From June 1998 to March 2008, Dr. Ennis was a Managing Director of ARCH Venture Partners, an early-stage venture firm, where he led seed and early-stage investments. He led the firm’s investments in Impinj (Nasdaq: PI) and Innovalight (acquired by DuPont). During his career, he has served on the boards of more than 20 venture-backed companies including Impinj, Innovalight, Kotura (acquired by Mellanox) and Artificial Muscle (acquired by Bayer Material Science). Prior to joining ARCH Venture Partners, Dr. Ennis held positions with Lucent Technologies, AT&T, and Bell Labs, where he led engineering projects for software development, speech recognition, network design and operations. Prior to Bell Labs, Dr. Ennis conducted research in Nuclear Physics at national and government laboratories in North America and Europe for seven years. Dr. Ennis is currently a Fellow at the Potomac Institute, a member of the University of Helsinki’s Commercialization Advisory Board, a member of the advisory board of Cybereason, a private global cybersecurity company, and an advisor to various companies in the defense industry. Dr. Ennis earned a Ph.D. and MS in Physics from Yale, an MBA from Wharton, and a BS in Math and Physics from the College of William & Mary where he was elected to Phi Beta Kappa. Dr. Ennis is a Kaufman Fellow. Dr. Ennis’s experience and track record in technology investing and early-stage business development brings substantial capabilities to our board of directors, with proprietary insight on leading-edge fields including machine learning, distributed computing and artificial intelligence. Dr. Karen Kerr will serve as a director following the completion of this offering. Dr. Kerr has over 25 years of experience in venture capital and technology investing. In May 2019, Dr. Kerr founded Exposition Ventures, a venture capital firm where she also serves as Managing Director. From April 2014 to April 2019, Dr. Kerr served as Executive Managing Director at GE Ventures, where she led investments in advanced manufacturing, supply chain technology, logistics, and enterprise software. Between 1996 and 2005, Dr. Kerr was a Managing Director at ARCH Venture Partners, where she helped grow assets under management to over $1 billion. Dr. Kerr has served as a director at Intellectual Ventures, and Senior Director of New Ventures and Alliances at the University of Southern California. Dr. Kerr started her career at Patricof & Co. and is a member of the Charter Class of Kauffman Fellows. Dr. Kerr is active on multiple boards, including the Kauffman Fellows, mHub, ORAU, the Clean Energy Trust and the Bryn Mawr College Board of Trustees. Dr. Kerr serves on the University of Chicago Physical Sciences Division and the Institute of Molecular Engineering Advisory Committees. Previously, Dr. Kerr served on the National Science Foundation’s Advisory Committee for the Small Business Innovative Research Program and on the National Institute for Standards and Technologies Visiting Committee on Advanced Technologies. Dr. Kerr earned a Ph.D. in Physical Chemistry from the University of Chicago and an A.B. in Chemistry from Bryn Mawr College. Dr. Kerr has been recognized as a Corporate Venture Capital Rising Star, a Crain’s Chicago Business Tech 50, one of LA’s Top Innovators, Crain’s Chicago Business 40 Under 40, and C200 Women Business Leaders. Dr. Kerr’s leadership roles and experience in both corporate ventures and institutional venture capital across numerous industries in advanced manufacturing, supply chain and logistics, and enterprise software add strong transactional experience and management capability to our board of directors. 101 Dr. Bernhard Stapp will serve as a director following the completion of this offering. Dr. Bernhard Stapp has served as President of CS-management GmbH, which provides consulting and advisory services to companies and investment firms with a focus on LED, OLED, photonics, cleantech and electronics materials, since November 2011. Between 2009 and 2011, Dr. Stapp served as Senior Vice President of Solid-State Lighting at OSRAM Licht AG, a global leader in optics and LED technology. Between 2001 and 2009, Dr. Stapp served in numerous roles at OSRAM Opto Semiconductors AG, including Chief Technology Officer and General Manager for LED and OLED components. Dr. Stapp began his career at Siemens AG where his roles included Head of Materials and Manufacturing, Group Leader of Functional Thin Films, and roles as Senior Scientist within the optical fiber, UV and ultrasound divisions. Dr. Stapp earned a Ph.D. in Metal Organics and a BS in Chemistry from the University Ulm in Germany. With his significant experience managing and advising various technology companies, particularly in the compound semiconductor and photonics space, we believe that Dr. Stapp will be a valuable addition to our board of directors. Number and Terms of Office of Officers and Directors Our board of directors will consist of five members and is divided into three classes with only one class of directors being appointed in each year, and with each class (except for those directors appointed prior to our first annual general meeting) serving a three-year term. In accordance with Nasdaq rules, we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors, consisting of Dr. [ ], will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Dr. [ ] and Dr. [ ], will expire at the second annual general meeting. The term of office of the third class of directors, consisting of Dr. [ ], will expire at the third annual general meeting. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated memorandum and articles of association. Director Independence Nasdaq’s listing standards require that a majority of our board of directors be independent within one year of our initial public offering. Our board of directors has determined that Dr. Kerr, Dr. Ennis and Dr. Stapp are “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive Officer and Director Compensation None of our executive officers or directors have received any cash compensation for services rendered to us. We will pay New Highland, LLC, of which our Chief Financial Officer is the managing member, for consulting services and the preparation of our financial statements for the period commencing March 1, 2021 until the consummation of our initial business combination as follows: (i) $10,000 for the preparation of the financial statements for the registration statement of which this prospectus forms a part; (ii) $5,000 for the preparation of the financial statements required to be filed in our Current Report on Form 8-K following the completion of this offering; (iii) $5,000 for the preparation of financial statements for each of our Quarterly Reports on Form 10-Q; and (iv) $10,000 for the preparation of financial statements for each of our Annual Reports on Form 10-K. Our sponsor, executive officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that are made to our sponsor, executive officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. 102 We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. Committees of the Board of Directors Upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will have two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 under the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. Audit Committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Dr. Kerr, Dr. Ennis and Dr. Stapp will serve as members of our audit committee. Under Nasdaq’s listing standards and applicable SEC rules, we are required to have three members of the audit committee, all of whom must be independent, subject to the exception described below. Dr. Kerr, Dr. Ennis and Dr. Stapp are independent. Dr. Kerr will serve as the chairman of the audit committee. Each member of the audit committee is financially literate and our board of directors has determined that Dr. Kerr qualifies as an “audit committee financial expert” as defined in applicable SEC rules. The audit committee is responsible for: •meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems; •monitoring the independence of the independent registered public accounting firm; •verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; •inquiring and discussing with management our compliance with applicable laws and regulations; •pre-approving all audit services and permitted non-audit services to be performed by our independent register

Holder Stats

1 0
% of Shares Held by All Insider 17.06%
% of Shares Held by Institutions 71.56%
% of Float Held by Institutions 86.27%
Number of Institutions Holding Shares 43

Mutual Fund Holders

Holder Shares Date Reported Value % Out
CrossingBridge Low Duration High Yield Fund 141515 2022-02-27 1400998 1.4200000000000002
CrossingBridge Ultra-Short Duration Fund 76149 2022-02-27 753875 0.76
Fidelity NASDAQ Composite Index Fund 3004 2022-02-27 29739 0.03
Saba Capital Income & Opportunities Fd 2703 2022-01-30 26651 0.03

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2022-05-27 Walleye Capital LLC 56,000 $560,000 0.0% -2.1% 0.560%
2022-05-23 Spring Creek Capital LLC 197,128 $1,960,000 0.1% +97.1% 1.971%
2022-05-17 Walleye Capital LLC 56,000 $560,000 0.0% -2.1% 0.560%
2022-05-17 Glazer Capital LLC 100,492 $1,000,000 0.0% 0 1.005%
2022-05-17 Saba Capital Management L.P. 40,846 $410,000 0.0% +8.7% 0.408%
2022-05-16 Goldman Sachs Group Inc. 67,880 $670,000 0.0% +4.8% 0.679%
2022-05-13 Basso Capital Management L.P. 167,119 $1,660,000 0.2% +4.8% 1.671%
2022-05-13 Spring Creek Capital LLC 197,128 $1,960,000 0.1% +97.1% 1.971%
2022-05-13 Cohanzick Management LLC 217,664 $2,160,000 0.5% 0 2.177%
2022-05-10 Karpus Management Inc. 92,241 $910,000 0.0% +3.3% 0.922%
2022-05-05 Lynwood Capital Management Inc. 197,910 $1,960,000 2.1% +2.6% 1.979%
2022-05-04 Wolverine Asset Management LLC 146,435 $1,450,000 0.0% -9.4% 1.464%
2022-03-15 Beryl Capital Management LLC 250,000 $2,460,000 0.1% +400.0% 2.500%
2022-02-15 Saba Capital Management L.P. 37,591 $370,000 0.0% +112.0% 0.376%
2022-02-11 MYDA Advisors LLC 149,000 $1,470,000 0.4% 0 1.490%
2022-02-09 Wolverine Asset Management LLC 161,589 $1,590,000 0.0% -14.3% 1.616%
2022-01-19 Cantor Fitzgerald Investment Adviser L.P. 98,000 $960,000 0.1% 0 0.980%
2021-12-14 Oaktree Capital Management LP 150,000 $1,480,000 0.0% 0 1.500%
2021-11-17 Altium Capital Management LP 200,000 $1,970,000 0.4% 0 1.942%
2021-11-16 Schonfeld Strategic Advisors LLC 15,000 $150,000 0.0% 0 0.146%
2021-11-16 Oaktree Capital Management LP 150,000 $1,480,000 0.0% 0 1.456%
2021-11-16 Whitebox Advisors LLC 250,000 $2,460,000 0.1% 0 2.427%
2021-11-16 Warberg Asset Management LLC 10,000 $99,000 0.0% 0 0.097%
2021-11-16 Beryl Capital Management LLC 50,000 $490,000 0.0% 0 0.485%
2021-11-16 CNH Partners LLC 197,128 $1,950,000 0.1% 0 1.914%
2021-11-16 CVI Holdings LLC 150,000 $1,480,000 0.1% 0 1.456%
2021-11-15 Ancora Advisors LLC 5,900 $58,000 0.0% 0 0.057%
2021-11-15 Polar Asset Management Partners Inc. 800,000 $7,880,000 0.1% 0 7.767%
2021-11-15 Rivernorth Capital Management LLC 11,172 $110,000 0.0% 0 0.108%
2021-11-15 Berkley W R Corp 384,873 $3,790,000 0.3% 0 3.737%
2021-11-12 Periscope Capital Inc. 370,093 $3,650,000 0.1% 0 3.593%
2021-11-12 Arena Capital Advisors LLC CA 500,000 $4,930,000 0.4% 0 4.854%
2021-11-12 Weiss Asset Management LP 428,988 $4,230,000 0.1% 0 4.165%
2021-11-12 Wolverine Asset Management LLC 188,500 $1,860,000 0.0% 0 1.830%
2021-11-12 Cohanzick Management LLC 242,965 $2,390,000 0.6% 0 2.359%
2021-11-10 Goldman Sachs Group Inc. 65,580 $650,000 0.0% 0 0.637%
2021-11-09 ATW Spac Management LLC 50,000 $490,000 0.1% 0 0.485%
2021-11-09 Basso Capital Management L.P. 199,896 $1,970,000 0.2% 0 1.941%

SEC Filings

Form Type Form Description Filing Date Document Link
8-K FORM 8-K 2022-07-19
DEFA14A DEFA14A 2022-06-30
8-K FORM 8-K 2022-06-30
DEF 14A DEF 14A 2022-06-24
UPLOAD 2022-06-23
8-K FORM 8-K 2022-06-22
CORRESP 2022-06-22
UPLOAD 2022-06-17
PRE 14A PRE 14A 2022-06-09
10-Q 10-Q 2022-05-16
SC 13G SC 13G 2022-04-15
10-K 10-K 2022-03-31
4 FORM 4 2022-02-28
4 FORM 4 2022-02-28
SC 13G SC 13G 2022-02-14
SC 13G SC 13G 2022-02-08
SC 13G FORM SC 13G 2022-02-07
SC 13G/A 2022-02-03
10-Q 10-Q 2021-11-15
10-Q FORM 10-Q 2021-09-02
8-K 8-K 2021-08-03
8-K FORM 8-K 2021-07-28
SC 13G SCHEDULE 13G 2021-07-26
8-K FORM 8-K 2021-07-23
424B4 424B4 2021-07-21
EFFECT 2021-07-19
CERT 2021-07-15
8-A12B FORM 8-A 2021-07-15
S-1/A S-1/A 2021-07-14
S-1/A S-1/A 2021-07-09
S-1 FORM S-1 2021-06-25
DRS 2021-04-09